<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941612</url>
  </required_header>
  <id_info>
    <org_study_id>H-21004012</org_study_id>
    <nct_id>NCT04941612</nct_id>
  </id_info>
  <brief_title>Use of the Bioabsorbable Activa IM-Nail™ in Pediatric Diaphyseal Forearm Fractures</brief_title>
  <official_title>Use of the Bioabsorbable Activa IM-Nail™ in Pediatric Diaphyseal Forearm Fractures: a Cohort Study of 30 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Fractures Interest Group, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Fractures Interest Group, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background&#xD;
&#xD;
      Pediatric diaphyseal forearm fractures are common and one of the most frequent reasons for&#xD;
      orthopedic care. Fractures in need of surgery are often treated with metal Elastic Stable&#xD;
      Intramedullary Nails (ESIN). Nail removal after 6-12 months is generally advocated. Surgical&#xD;
      hardware removal has few complications; however, it is a substantial burden on the child, the&#xD;
      family and healthcare economy. Bioabsorbable Intramedullary Nails (BIN) have been developed&#xD;
      for the same indications as metal ESIN. The use of bioabsorbable implants would deem hardware&#xD;
      removal unnecessary and relieve the child of further surgery and reduce healthcare costs.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      The investigators aim to recruit all children in the catchment area of Herlev and Gentofte&#xD;
      University Hospital (Copenhagen, Denmark) with acute unstable diaphyseal forearm fractures.&#xD;
      Participants will be operated with BIN and followed consecutively for 2 years with interim&#xD;
      analysis of data after 6 months. The investigators will report radiological healing using the&#xD;
      Radiographic Union Score (RUS) 3 months after surgery together with any adverse events during&#xD;
      follow-up.&#xD;
&#xD;
      Discussion&#xD;
&#xD;
      This study will provide important preliminary data and asses the feasibility of using the&#xD;
      bioabsorbable Activa IM-Nail™ in pediatric diaphyseal forearm fractures. This study is a&#xD;
      pilot study for initiating an RCT comparing BIN to metal ESIN hypothesizing that BIN is not&#xD;
      an inferior treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">May 25, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cohort study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic Union Score (RUS)</measure>
    <time_frame>3 months</time_frame>
    <description>RUS is a score derived from assessing AP and lateral radiographs. Each bone cortex (anterior, posterior, medial and lateral) is assigned a score of 1 to 3. A cortex with a visible fracture line and no callus is given a score of 1, a cortex with callus but a visible fracture line is scored as 2 and a cortex with bridging callus and no visible fracture line is scored as 3. Scores are added to give a minimum score of 4 (definitely not healed) and a maximum of 12 (definitely healed). 12 is best.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Faces Pain Scale - Revised (FPS-R)</measure>
    <time_frame>3 months</time_frame>
    <description>To measure the outcome of pain in children below 8 years of age. Pain evaluated by the child selecting 1 of 6 faces that represents their feeling of pain. Faces are scored 0, 2, 4, 6, 8 or 10. Scale 0-10 with 2 point increments. 0 = no pain, 10= very much pain. 0 is best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilateral elbow and forearm range of motion</measure>
    <time_frame>3 months</time_frame>
    <description>Measured in degrees by goniometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>3 months</time_frame>
    <description>Pain evaluated by the child putting a mark on a 10 cm long line. Most left=no pain, most right=worst possible pain. Distance from most left to the child's mark is measured with a ruler. 1 mm = 1 point. Value is given with 1 decimal, e.g. 64 mm = 6,4 points.&#xD;
Scale 0.0-10.0. With 0 = no pain, 10= worst possible pain. 0 is best.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Fracture Fixation, Intramedullary</condition>
  <condition>Forearm Fracture</condition>
  <condition>Fracture Healing</condition>
  <condition>Child, Only</condition>
  <condition>Implant Complication</condition>
  <arm_group>
    <arm_group_label>Activa IM-Nail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Activa IM-Nail</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Activa IM-Nail</intervention_name>
    <description>PLGA bioabsorbable intramedullary nail</description>
    <arm_group_label>Activa IM-Nail</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute traumatic diaphyseal forearm fracture of the radius, ulna or both&#xD;
&#xD;
          -  Fractures need to be complete (not unicortical or green stick)&#xD;
&#xD;
          -  Displaced more than 50% of bone width or angulated more than 10° in any plane or&#xD;
             irreducible or unstable after reduction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        We exclude patients&#xD;
&#xD;
          -  with fractures that are well managed conservatively (undisplaced or minimally&#xD;
             displaced)&#xD;
&#xD;
          -  with previous ipsilateral forearm fracture&#xD;
&#xD;
          -  with fractures unsuited for intramedullary nailing (e.g. multifragmentary, metaphyseal&#xD;
             or epiphyseal)&#xD;
&#xD;
          -  with fractures with ipsilateral wrist or elbow involvement (e.g. Monteggia or Galeazzi&#xD;
             variants)&#xD;
&#xD;
          -  unable to participate in follow-up&#xD;
&#xD;
          -  with existing bone pathology (e.g. tumor, osteogenesis imperfecta, degenerative&#xD;
             disease)&#xD;
&#xD;
          -  in whom internal fixation is otherwise contraindicated (e.g. active or potential&#xD;
             infection)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten J Andersen, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Morten J Andersen, MD</last_name>
    <phone>004538681479</phone>
    <email>mortenjonandersen@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herlev and Gentofte University Hospital</name>
      <address>
        <city>Herlev</city>
        <state>Capital Region</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten J Andersen, MD</last_name>
      <phone>004538681479</phone>
      <email>morten.jon.andersen@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Fractures Interest Group, Denmark</investigator_affiliation>
    <investigator_full_name>Morten Jon Andersen</investigator_full_name>
    <investigator_title>Consultant Orthopedic Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 24, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT04941612/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

